European Equities Traded in the US as American Depositary Receipts Little Changed in Tuesday

MT Newswires Live
Oct 28

European equities traded in the US as American depositary receipts were little changed late Tuesday morning, edging 0.01% lower to 1,604.02 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by biotech firm Evaxion (EVAX) and telecommunications company Nokia (NOK), which rose 4.5% and 1.7% respectively. They were followed by lender Banco Santander (SAN) and semiconductor company Sequans Communications (SQNS), which were up 1.3% and 0.2% respectively.

The decliners from continental Europe were led by 3D printer company Materialise (MTLS) and accommodations booking site trivago (TRVG), which fell 2.1% and 1.8% respectively. They were followed by consumer goods giant Unilever (UL) and pharmaceutical company Sanofi (SNY), which were down 1.6% and 1.1% respectively.

From the UK and Ireland, the gainers were led by lender HSBC (HSBC) and pharmaceutical company Silence Therapeutics (SLN), which advanced 4% and 3.2% respectively. They were followed by biopharmaceutical companies Akari Therapeutics (AKTX) and Mereo BioPharma Group (MREO), which increased 3.1% and 1% respectively.

The decliners from the UK and Ireland were led by cruise line operator Carnival (CUK) and biotech firm Autolus Therapeutics (AUTL), which dropped 4.3% and 3.9% respectively. They were followed by biopharmaceutical companies Biodexa Pharmaceuticals (BDRX) and NuCana (NCNA), which lost 3.3% and 1.2% respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10